It is a questionable disease in the field of genetic metabolism, with clinical performance being complex and often involving multiple systems. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Treatment and management of HPE1 requires the development of personalized treatment regimens, typically including drug therapy, rehabilitation interventions, and regular follow-up management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult-to-treat genetic metabolic disorders.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely schemes depending on the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HPE1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.